Abstract
Background: B. cepacia complex (Bcc) is an emerging pathogenic organism that can cause many nosocomial infections among hospitalized patients. Inadequate laboratory facilities for B. cepacia complex detection and subsequently inappropriate treatment are considered a major cause for poor therapy outcomes. Methods: This project was aimed to investigate phenotype production of ESBL, AmpC, and Carbapenemase among 47 B. cepacia complex isolated from different Sebha health care facilities. Results: Our data showed that 44.68% were ESBL producers, 57.44% were AmpC producers, while only 29.78% produced carbapenemase. In this study, antibiotics susceptibility of Bcc isolates was variable, 100 % resistant to Ticarcillin/clavulanic acid, 85 % resistant to sulfamethoxazole-trimethoprim, 76 % resistant to Ticarcillin/clavulanic Chloramphenicol, 57 % to Ceftazidime, and 55 % to Tetracyclines, 44% to Ciprofloxacin and 31% to Meropenem. Conclusion: In conclusion, this study shows that Bcc species have a higher resistance level attributed to several mechanisms. This high resistance needs careful antimicrobial prescribing regulations, and urgent implementation of infection prevention control is necessary.